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Abstract  34 
Objective  35 
To determine the diagnostic and prognostic significance of neurofilament light chain 36 
(NfL), TAR DNA-binding protein 43 (TDP-43), and total tau (t-tau) in cerebrospinal 37 
fluid (CSF) and plasma of patients with amyotrophic lateral sclerosis (ALS). 38 
Methods  39 
This was a single-center, prospective, longitudinal study. CSF and plasma samples were 40 
collected at the time of enrollment from a discovery cohort of 29 patients with ALS and 41 
29 age-matched controls without neurodegenerative disease. In a validation cohort, 42 
there were 46 patients with ALS, and 46 control (not age-matched) patients with motor 43 
weakness resulting from neuromuscular diseases. NfL, TDP-43, and t-tau levels in CSF 44 
and plasma were measured using ultrasensitive single molecule assay (Simoa) 45 
technology. 46 
Results  47 
The following findings were reproducibly observed among the discovery and validation 48 
cohorts: increased levels of CSF NfL, plasma NfL, and CSF TDP-43 in ALS compared 49 
with control groups; shorter survival associated with higher levels of CSF and plasma 50 
NfL. When the CSF NfL and CSF TDP-43 levels were combined, the areas under the 51 
ROC curves (AUC) were slightly improved relative to AUCs for each biomarker alone.  52 
Conclusion  53 
CSF and plasma NfL may not only serve as diagnostic biomarkers but also provide a 54 
measure of disease progression. CSF TDP-43 is also useful as a diagnostic biomarker of 55 
ALS, but has no prognostic value. The combined use of CSF NfL and CSF TDP-43 may 56 
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be a useful biomarker for the diagnosis of ALS.   57 
Key words: Amyotrophic lateral sclerosis, biomarker, TDP-43, neurofilament light 58 
chain, Simoa. 59 
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Introduction  60 
    There is an urgent need for molecular biomarkers in biofluids for the diagnosis of 61 
amyotrophic lateral sclerosis (ALS) 1. At present, the most promising biomarker for 62 
ALS is neurofilament light chain (NfL). Elevated levels of NfL in CSF and blood 63 
plasma/serum have been reported in patients with ALS compared with controls; 64 
moreover, they were associated with poor outcomes 2-3. TAR DNA-binding protein 43 65 
(TDP-43) positive inclusions are found in approximately 97% of patients with ALS. 66 
This has led to the investigation of TDP-43 as a potential molecular biomarker for ALS. 67 
Overall, these studies have identified increased levels of TDP-43 in CSF from ALS 68 
patients compared with controls 4. An elevated level of TDP-43 has also been reported 69 
in plasma from ALS patients in one case-control study 5. However, the absolute 70 
concentrations of TDP-43 in CSF and plasma have varied across studies, suggesting that 71 
TDP-43 immunoassays are inconsistent for measuring this protein within biofluids 4. 72 
The other candidate is Tau. Recent studies reporting elevated levels of CSF total-Tau (t-73 
tau) in ALS patients compared with controls have generated novel interest in the 74 
diagnostic potential of t-tau for ALS 6, 7. However, there are conflicting results 8, 9  and 75 
the prognostic significance of plasma t-tau in ALS has so far received little attention. 76 
 Considering the lack of comprehensive analysis of these three biomarkers for ALS, we 77 
conducted the present study to determine the diagnostic and prognostic potential of 78 
TDP-43 and t-tau as molecular biomarkers, compared with NfL not only in CSF but 79 
also in blood plasma. 80 
 81 
 82 
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Methods  83 
Study design, ethical approvals, and subject recruitment 84 
     All study subjects provided written informed consent before participation and the 85 
study protocols were approved by the University Ethics Committee (ERB-G-12, Kyoto 86 
Prefectural University of Medicine, Kyoto, Japan). Informed consent from patients was 87 
obtained when possible and also from the nearest relative. Study procedures were 88 
designed and performed in accordance with the Declaration of Helsinki. The discovery 89 
cohort consisted of 29 individuals with possible, probable, or definite ALS diagnosed 90 
according to the revised El Escorial criteria (the ALS group of the discovery cohort) 10 91 
and 29 age-matched controls (the control group of the discovery cohort). All patients 92 
with possible ALS when their CSF and plasma were measured, were confirmed to show 93 
conversion to probable or definite ALS within the follow-up period. The control group 94 
participants had non-neurodegenerative diseases and presented with no neurological 95 
symptoms. They were enrolled from the registration for neurodegenerative and 96 
dementia disorders in Kyoto Prefectural University of Medicine (KPUM) from 97 
September 2009 to March 2014. All participants of the discovery cohort underwent CSF 98 
and plasma collection. The sample size of the discovery cohort was set according to the 99 
effect size of previous biomarker studies 11 12. The validation cohort comprised 46 100 
individuals with suspected, possible, probable, or definite ALS diagnosed with the same 101 
criteria as for the discovery cohort (the ALS group of the discovery cohort) and 46 102 
patients with motor weakness resulting from neuromuscular diseases (the control group 103 
of the validation cohort), comprising: chronic inflammatory demyelinating 104 
polyneuropathy (CIDP: N=17), Gullain-Barre syndrome (GBS: N=18), multifocal 105 
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motor neuropathy (MMN: N=6), and inclusion body myositis (IBM: N=5). As described 106 
above, suspected and possible ALS patients were confirmed to show conversion to 107 
probable or definite ALS within the follow-up period. They were enrolled from KPUM 108 
from April 2014 to May 2018. The sample size of the discovery cohort was set based on 109 
the data from discovery cohort. Of note, not all participants in the validation cohort 110 
provided both blood and CSF samples. Because relatively young individuals were 111 
included in the control group, the ALS and control groups were not age-matched in the 112 
validation. All measurements of the biomarkers were done on a Simoa HD-1 Analyzer 113 
(Quanterix, Lexington, MA, USA) by commercially available kits. TDP43 kit used in 114 
the study was developed with antibodies against the amino acid residues between 203 – 115 
209 and the C-terminal region and therefore mainly target the C-terminal part of the 116 
protein.  For detailed information about plasma and CSF sampling, measurements of the 117 
biomarkers as well as statistical analyses see supplementary methods.  118 
      119 
Bias 120 
Our data are from patients who agreed to participate in this study and agreed to receive 121 
plasma collection or lumbar puncture for the diagnosis of ALS or other disorders. 122 
 123 
Data availability statement 124 
Any anonymized data not published in the article will be shared upon request from any  125 
qualified investigator. 126 
 127 
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Results 128 
Patient characteristics. 129 
     The demographic characteristics of the discovery and validation cohorts are 130 
summarized in Table 1 (for clinical information and raw data on biomarker 131 
concentrations, see Supplementary Tables 1 and 2). There was no significant difference 132 
in age (P=1.000) or sex (P=0.7840) between the ALS and control groups in the 133 
discovery cohort. In the validation cohort, the median age of the control group was 134 
significantly younger than that of the ALS group (P<0.0001), while there was no 135 
significant difference in sex between the two groups (P=0.3696).  136 
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Table 1 137 
Category Specific diagnosis N Sex(M:F) Age 
The discovery cohort 
    
ALS 
 
29 18:11 65.41±12.34 
Control 
(non-neurodegenerative control) 
See Supplementary Table 1B 29 19:10 66.40±9.2 
 
Difference between the groups: P=1.000 P=0.7840 
The validation cohort 
    
ALS 
 
46 29:17 71.36±9.27 
Control  
(patients with motor weakness 






Difference between the groups: P=0.3696 P<0.0001 
 
CIDP 17 14:3 60.06±14.45 
 
GBS 18 11:7 50.67±23.80 
 
MMN 6 5:1 48.50±21.03 
 
IBM 5 4:1 76.00±2.45 
 138 
GBS: Gullain-Barre syndrome, MFS: Millar-Fisher syndrome, CIDP: chronic 139 
inflammatory demyelinating polyneuropathy, MMN: multifocal motor neuropathy 140 
 141 
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Concentrations of biomarkers in the discovery cohort. 142 
     The concentrations of TDP-43, NfL, and t-tau in the samples from the discovery 143 
cohort are summarized in Figure 1. In the case of TDP-43, both plasma (P=0.0035, 144 
Figure 1A) and CSF levels (P<0.0001, Figure 1B) of this marker were elevated in the 145 
ALS group compared with the control group. This was also the case for NfL with 146 
increased levels found in both plasma (P=0.0299, Figure 1C) and CSF (P<0.0001, 147 
Figure 1D) from the ALS group compared with the control group. Finally, t-tau levels 148 
were significantly lower in the ALS group only in plasma (P=0.0178, Figure 1E), and 149 
not in CSF (P=0.1062, Figure 1F). 150 
ROC analysis of biomarkers in the discovery cohort. (for data, see Supplementary 151 
Figure 1) 152 
     According to ROC analysis of the discovery cohort, CSF NfL generated the highest 153 
area under the curve (AUC) value (AUC=0.8347, Supplementary Figure 1D). The 154 
second highest AUC value was observed with CSF TDP-43 (AUC=0.8205, 155 
Supplementary Figure 1B).  156 
Correlation between levels of biomarkers in CSF and plasma in the discovery 157 
cohort. (for data, see Supplementary Figure 2) 158 
     There was a significant positive correlation between NfL levels of plasma and CSF 159 
taken from each patient with ALS in the discovery cohort (solid line, P<0.0001,). Such 160 
a significant CSF-plasma correlation was also identified in the control group (dashed 161 
line, P=0.0013) (Supplementary Figure 2B).  Neither TDP-43 nor t-tau levels showed 162 
any plasma-CSF correlation in either of the groups (TDP-43 in the ALS group: 163 
P=0.2279, TDP-43 in the control group: P=0.9252, t-tau in the ALS group: P=0.1024, t-164 
tau in the control group: P=0.3463) (Supplementary Figure 2A and C). 165 
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Biomarkers and survival times in the discovery cohort. 166 
     All members of the ALS group in the discovery cohort were included in log-rank 167 
analysis (Figure 2). Nineteen patients reached the endpoint of death, tracheostomy, or 168 
invasive ventilation during the follow-up period. Survival times ranged from 17 to 169 
2,793 days (median: 575 days) (Supplementary Table 1B). Patients with ALS were 170 
subdivided into two groups according to the levels for each of the biomarkers: a low-171 
level group (< median value), and a high-level group (≥ median value). When 172 
comparing the high and low level groups, significant differences were noted in plasma 173 
NfL (P=0.0248, Figure 2C), CSF NfL (P=0.0207, Figure 2D), and CSF t-tau (P=0.0124, 174 
Figure 2F), while there is no significant difference in plasma TDP-43, CSF TDP-43, or 175 
plasma t-tau (Figure 2A, B, E). The high-level groups were associated with shorter 176 
survival compared with the low-level groups, for plasma NFL, CSF NfL, and CSF t-tau. 177 
After age-adjustment in multivariate analysis, the high levels of plasma and CSF NfL 178 
still retained significant prognostic value (plasma NfL, Hazard ratio (HR) = 6.800, 179 
P=0.003; CSF NfL, HR=7.727, P=0.002), while the association between CSF t-tau and 180 
survival did not reach significance (CSF t-tau, HR=2.875, P=0.065). 181 
Concentrations of biomarkers in the validation cohort. 182 
     The concentrations of TDP-43, NfL, and t-tau in the validation cohort are 183 
summarized in Figure 3.  On comparing ALS and control groups, significant elevations 184 
of biomarker concentrations in the ALS group were reproduced for CSF TDP-43 185 
(P=0.087, Figure 3B), plasma NfL (P=0.0031, Figure 3C), and CSF NfL (P<0.0001, 186 
Figure 3D), while neither plasma TDP-43 nor plasma t-tau levels were different 187 
between the groups, in contrast to those in the discovery cohort. CSF t-tau levels in the 188 
ALS group were significantly higher than those in the control group in the validation 189 
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cohort, although such a difference was not observed in the discovery cohort. Those 190 
significant differences were reproducibly confirmed by multiple comparison with the 191 
Kruskal-Wallis test among the ALS group and subgroups of the controls (CIDP, GBS, 192 
MMN, and IBM). Post-hoc analysis of Dunn’s multiple comparison tests revealed 193 
significantly higher levels of CSF TDP-43 in the ALS group compared with those in the 194 
CIDP subgroup, CSF NfL in the ALS group compared with those in the CIDP and GBS 195 
subgroups, and CSF t-tau in the ALS group compared with those in the CIDP subgroup. 196 
Considering the age difference between the ALS and control groups, we reanalyzed 197 
those comparisons after the exclusion of individuals younger than 60 years old 198 
(Supplementary Figure 3). There was no significant difference in age between the ALS 199 
(n=42) and control (n=24) groups, consisting of individuals aged no younger than 60. In 200 
these advanced age groups, comparisons between groups regarding biomarkers showing 201 
significant differences between the groups based on raw data (CSF TDP-43, CSF NfL, 202 
plasma NfL, and CSF t-tau) were conducted. Significant elevation of CSF TDP-43 and 203 
CSF NfL and plasma NfL levels in the ALS group compared with those in  controls was 204 
preserved (P=0.004 in Supplementary Figure 3A, P=0002 in Supplementary Figure 3B, 205 
and P=0.0156 in Supplementary Figure 3C, respectively), while the difference between 206 
the groups regarding CSF t-tau did not reach significance (Supplementary Fig. 3D).  207 
Biomarkers and survival times in the validation cohort. 208 
     Not all patients with ALS in the validation cohort were included in the log-rank 209 
analysis due to missing samples. We performed survival analysis involving 20 ALS 210 
patients with plasma biomarker data and 41 ALS patients with CSF biomarker data 211 
(Figure 4). In those patients, 10 patients in plasma biomarker analysis and 18 patients in 212 
CSF biomarker analysis reached the endpoint. Survival times ranged from 28 to 1,592 213 
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days (median: 305 days) (Supplementary Table 2B). The high-level group showed 214 
significantly shorter survival compared with the low-level group for plasma NfL 215 
(P=0.0178, Figure 4C) and CSF NfL (P=0.0284, Figure 4D), corresponding with the 216 
results in the discovery cohort. However, the significant difference in CSF t-tau was not 217 
reproduced (Figure 4F). After age-adjustment, the high levels of plasma and CSF NfL 218 
still exhibited significant prognostic values (HR=12.262, p=0.041 and HR=4.83, 219 
P=0.01, respectively). 220 
ROC analysis of composite biomarkers in discovery and validation cohorts 221 
regarding CSF TDP-43, CSF NfL and plasma NfL 222 
     Regarding the CSF TDP-43, CSF NfL, and plasma NfL that showed significant 223 
elevation in the ALS compared with control groups for both discovery and validation 224 
cohorts, we calculated composite parameters of the products of CSF NfL x CSF TDP-225 
43, of CSF NfL x plasma NfL, and of  plasma NfL x CSF TDP-43 (Figure 5). In both 226 
cohorts, the composition of CSF NfL and CSF TDP-43 provided better performance in 227 
terms of the AUC value compared to those in each biomarker alone (AUC=0.8430 and 228 
0.9493 in the discovery and validation cohorts, respectively, whereas the 229 
discriminability in the product of CSF NfL x plasma NfL was inferior to that in the CSF 230 
NfL alone in the discovery cohort. The AUC value for composition of plasma NfL and 231 
CSF TDP-43 (0.6813) could not exceed that in CSF TDP-43 alone. The combined 232 
analyses for the CSF and plasma biomarkers in the validation were not performed 233 
because more than half of participants of the validation cohort did not underwent both 234 
plasma and CSF collection. 235 
Combined analysis of validation and discovery cohorts regarding plasma TDP-43, 236 
CSF TDP-43, plasma t-tau, and CSF t-tau 237 
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 Regarding the levels of plasma TDP-43, plasma t-tau, and CSF t-tau, for which 238 
inconsistent differences were found between ALS patients and controls when 239 
comparing the two cohorts, we conducted a combined analysis based on data from 240 
internal controls. Levels of plasma TDP-43 in the combined ALS group were higher 241 
than those in the combined control group (P=0.0137).  Levels of plasma t-tau were not 242 
different between these groups (P=0.228), while CSF t-tau was significantly elevated in 243 
the combined ALS group compared with the combined control group (P=0.0006) 244 
(Figure 6).  We also recalculated survival analyses in the combined ALS group for the 245 
biomarkers. Both plasma and CSF NfL levels were associated with shorter survival 246 
(P=0.0002 and P=0.0193, respectively). Those significances were still preserved after 247 
age-adjustment (HR=7.611, P<0.001 and HR=4.567,  P<0.001, respectively). 248 
Meanwhile, there was no significant difference in survival between the high- and low-249 
level groups based on TDP-43 and t-tau levels in plasma and CSF (Figure 7). 250 
 251 
Discussion 252 
     Biomarker profiles of TDP-43, NfL, and t-tau in ALS have been comprehensively 253 
investigated 4. However, most previous studies have focused on one or two of these 254 
biomarkers. Moreover, the diagnostic or prognostic value of plasma TDP-43 or plasma 255 
t-tau in ALS has remained uncertain because of the difficulty of stable measurement. To 256 
the best of our knowledge, this study is the first to comprehensively measure levels of 257 
all of these three candidate biomarkers, not only in CSF but also, simultaneously, in 258 
plasma. The current study showed the following three major findings that were 259 
consistent across the discovery and validation cohorts.  260 
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     First, CSF NfL was significantly elevated in the ALS compared with control 261 
groups. Furthermore, the potential prognostic value of elevated levels of CSF NfL, in 262 
terms of shorter survival time, was observed after stratifying cohorts according to the 263 
median CSF NfL levels. These confirm findings gathered in retrospective case-control 264 
studies and prospective observations 2 3 13-18. On the other hand, the AUC value used to 265 
discriminate between ALS patients and controls in our study (0.8347) was slightly 266 
lower than in a previous meta-analysis: 0.90; 95% confidence interval, 0.87–0.92 18. We 267 
consider that this difference may be associated with the research design, control-group 268 
choice, and ethnic differences.  269 
     Second, plasma NfL was significantly higher in the ALS group than in the controls, 270 
and higher plasma NfL was associated with a shorter survival. Those results are in 271 
agreement with observations in previous case-control studies using serum 17 19 20 and 272 
plasma 14. Overall, these findings support the possibility that NfL not only in CSF but 273 
also plasma, can serve as a promising biomarker for the diagnosis and monitoring of 274 
disease progression of ALS. The fact that CSF and plasma NfL shared the same 275 
biomarker profile is reasonable when we consider the correlation between them in each 276 
participant of the discovery cohort. Such plasma-CSF correlation in NfL has been 277 
observed not only in patients with ALS 20 but also in patients with Alzheimer’s disease, 278 
multiple sclerosis, and control individuals 21 22. The plasma-CSF correlation in our 279 
controls was slightly irregular; actually, the association in the controls did not fit a linear 280 
correlation, in contrast to that in the ALS group. This inconsistency may be due to 281 
heterogeneity caused by the use of disease controls in this study. 282 
     Third, we noted significantly higher levels of TDP-43 in CSF of ALS patients than 283 
those in controls. This result is consistent with previous observations, including two of 284 
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our studies and one meta-analysis 11 12 23-26. TDP-43 is considered to be a disease-285 
specific biomarker reflecting TDP-43 pathology in the central nervous system As 286 
expected, the AUC values, representing the ability to discriminate between ALS patients 287 
and controls, were improved by combining CSF NfL with CSF TDP-43 relative to that 288 
in each biomarker alone. This observation was consistently found across the both 289 
cohort, suggesting that CSF TDP-43 could serve as a biomarker complementary to NfL 290 
in the diagnosis of ALS. CSF NfL was recently reported to have a diagnostic potential 291 
even for presymptomatic ALS 19.  However, at present, no one can predict which kind 292 
of neurodegeneration will develop in individuals with elevated CSF NfL levels due to 293 
its lack of disease specificity 27. The combined use of CSF NfL and CSF TDP-43 may 294 
be recommended for such people suspected to have neurodegeneration with 295 
undetermined pathology. This biomarker-combination could also facilitate enrollments 296 
of clinical trials toward preemptive therapy for ALS.   Of note here, there is controversy 297 
regarding the validity of the hypothesis that elevation of CSF TDP-43 is specifically 298 
caused by TDP-43 proteinopathy. Immunoblotting shows that the identification of TDP-299 
43 in biofluids by the commonly applied antibody combinations used for quantification 300 
represent a 45-kDa full-length form of TDP-43, rather than disease-specific truncated 301 
forms 23 28. Therefore, no evidence has been reported to date that the elevation of CSF 302 
TDP-43 detected by our method results from TDP-43 pathology. Taking these facts into 303 
consideration, it is possible that increased CSF TDP-43 in ALS might simply be a 304 
consequence of neuronal cell damage, similar to NfL. To develop a more disease-305 
specific biomarker in the future, measurements of C-terminal truncated or 306 
phosphorylated forms of TDP-43, if possible extracted from neuron-derived exosomes, 307 
would be ideal candidates. 308 
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 Levels of plasma TDP-43, plasma t-tau, and CSF t-tau were significantly different 309 
between the ALS and control groups in both the discovery and validation cohorts, 310 
although the results were not preserved across these cohorts. In the combined analysis, 311 
the significant elevation of plasma TDP-43 and CSF t-tau in the ALS group was 312 
repeatedly observed, whereas the significant difference in plasma t-tau between the 313 
groups was not reproduced. The significant elevation of plasma TDP-43 in the ALS 314 
group agrees with one case-control study 5. The previous measurement of plasma TDP-315 
43 based on conventional immunoassay had the problem of low sensitivity, and actually 316 
failed to accurately quantify more than 70% of samples due to signals being lower than 317 
the detection limit 5. In contrast, we could detect measurable signals from the whole 318 
plasma samples. This advantage may be due to the SIMOA analyzer, with 100- to 319 
1,000-fold higher sensitivity than conventional assays 29. This result provides evidence 320 
supporting the potential diagnostic value of plasma TDP-43 for ALS as well as 321 
usefulness of such new digital analytical platforms for the development of blood-based 322 
biomarkers of the disease.  323 
     No difference in CSF levels of t-tau were found in the discovery cohort, while levels 324 
of this biomarker were significantly elevated in the ALS group compared with the 325 
controls in the validation cohort, and on combined analysis. Previous studies have 326 
yielded similar inconsistent results regarding CSF levels of t-tau in ALS patients, which 327 
ranged between normal 16, 8, 9, 30, 31 and increased levels 6 7, 32. This inconsistency might 328 
be linked to the inherent variability of the disease; for example, variability in release of 329 
tau from motor neurons during disease progression. Thus, differences in the disease 330 
stage and disease progression rate of enrolled patients may have contributed to the 331 
variable findings of CSF t-tau. On the other hand, levels of plasma t-tau were 332 
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significantly lower in the ALS than control group in the discovery cohort, but this result 333 
was not reproduced in the validation cohort or in the combined study. There is one 334 
published case control study on plasma t-tau in patients with FTD and controls, in 335 
which levels of plasma t-tau were not different between patients with pathogenic 336 
mutations causing TDP-43 proteinopathy (i.e., mutation of GRN or C9orf72) but they 337 
were significantly elevated in patients with MAPT mutations compared with controls. 338 
Our results on plasma t-tau agree with this report in that plasma t-tau levels were not 339 
different between patients with TDP-43 proteinopathy and controls. 340 
 In survival analysis all of the biomarkers except for plasma and CSF NfL failed to 341 
exhibit any prognostic value, consistently across the discovery and validation cohorts. 342 
We previously reported that lower CSF TDP-43 levels were correlated with shorter 343 
survival 12. However, the current study did not reproduce the results in the discovery 344 
and validation cohorts, or on combined analysis. This discrepancy may be due to the 345 
confounder that levels of CSF TDP-43 vary depending on the stage of ALS 11. A recent 346 
study argued that higher levels of CSF t-tau are associated with shorter survival 6. This 347 
result was consistent with that in our discovery cohort, but was not reproduced in either 348 
the validation cohort or on combined analysis. This inconsistency may have been 349 
caused by the shortness of the follow-up period in the validation cohort, which was 350 
around half of that in the previous study. Longer observation would be needed to 351 
validate the usefulness of CSF t-tau as a prognostic biomarker. 352 
     We acknowledge that the relatively small sample size was a major limitation of the 353 
study. Furthermore, as mentioned above, the short follow-up period may have weakened 354 
the statistical power to detect an association between survival and the biomarkers. In the 355 
future, case-control as well as longitudinal studies involving sufficient numbers of 356 
Commented [K1]: I have erased the sentence because stage 
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participants with a longer follow-up period will be necessary to confirm our findings 357 
and promote the clinical application of biomarker-supported diagnosis and progression 358 
monitoring of ALS. 359 
 360 
Conclusions 361 
     This is the first study comprehensively analyzed the three candidate biomarkers for 362 
ALS in CSF and plasma. NfL levels in CSF and plasma were significantly elevated in 363 
the ALS patients compared with controls. Moreover, higher levels of those markers 364 
were associated with shorter survival. Both may serve as not only diagnostic biomarkers 365 
but also measures of disease progression. TDP-43 levels in CSF, which were increased 366 
in the ALS patients compared with controls but were not associated with survival 367 
periods, may only be useful as a diagnostic biomarker. The discrimination ability 368 
between ALS and control was improved by the combined use of CSF TDP-43 and CSF 369 
NfL, therefore CSF TDP-43 could serve as a biomarker complementary to NfL in the 370 
diagnosis of ALS. Plasma TDP-43 and CSF t-tau may be elevated in ALS patients and, 371 
therefore, be of diagnostic value; however, the present results still need future validation 372 
in a larger cohort. 373 
 374 
Author Contributions 375 
T. O. and Y.K assisted with patient enrollment, data analysis, and interpretation. H.T., 376 
F.K-M., and M.S. performed laboratory work and data analysis. Y.T. and Y.N. 377 
contributed to data collection. D.A. and T.M. participated in review and revision of the 378 
manuscript. T.K. and T.T were involved with conceptualization and design of the study, 379 
Kasai and Kojima, et al.  Page 20 
patient enrollment, data collection, interpretation of the data, and review of the 380 
manuscript. All authors reviewed the drafts and approved the final version of the 381 
manuscript. 382 
 383 
Competing interests and funding 384 
The authors have no competing financial interests. Also, no non-financial conflicts of 385 
interest exist. This work was supported in part by grants from the Japan Agency for 386 
Medical Research and Development (AMED) (18dk0207030h0003 and 387 
19ek0109222h0003 to T.T.) and by Grants-in-Aid (Nos. 15K09319 and 18K07506 to 388 
T.K. and 18K15461 to H.T.) from the Ministry of Education, Culture, Sports, Science 389 






  396 
Kasai and Kojima, et al.  Page 21 
Figure 1 397 
Scatter plots of biomarkers levels in the discovery cohort. 398 
ALS (n=29) and control (n=29). Levels of plasma and CSF TDP-43 (A, B), NfL (B, C), 399 
t-tau (D, E) are presented. Bars indicate median values. The P-value generated by 400 
Mann-Whitney’s U test is shown above each graph. n.s: not significant. 401 
 402 
Figure 2 403 
Kaplan-Meier survival curves in ALS patients of the discovery cohort according to 404 
biomarkers levels.  405 
(A): plasma TDP-43, (B): CSF TDP-43, (C): plasma NfL, (D): CSF NfL, (E): plasma t-406 
tau, (F): CSF t-tau. The squares and circles indicate an event (death, tracheostomy, or 407 
invasive ventilation). Patients were subdivided into two groups according to the cut-off 408 
biomarker levels. The cut-off value in each graph was set as the median value of the 409 
corresponding biomarker within the ALS group. The red lines with red squares 410 
represent patients with levels of biomarkers no lower than the cut-off (the high-level 411 
group). The black lines with black circles represent those with levels lower than the cut-412 
off (the low-level group). 413 
 414 
Figure 3 415 
Scatter plots of biomarkers levels in the validation cohort. 416 
Control (n=46) and ALS (n=46). Levels of plasma and CSF TDP-43 (A, B), NfL (B, C), 417 
t-tau (D, E) are presented. Bars indicate median values. The P-value generated by 418 
Mann-Whitney’s U test between the ALS and whole control group is shown above each 419 
graph. Significant differences were reproducibly confirmed by multiple comparison 420 
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tests with the Kruskal-Wallis test among the ALS group and subgroups of the controls 421 
(CIDP, GBS, MMN, and IBM). Dashed bars and asterisks indicate significant 422 
differences (P<0.05) between the groups by post-hoc analysis of Dunn’s multiple 423 
comparison procedure. n.s: not significant. 424 
 425 
Figure 4 426 
Kaplan-Meier survival curves in ALS patients of the validation cohort according to 427 
biomarkers levels.  428 
(A): plasma TDP-43, (B): CSF TDP-43, (C): plasma NfL, (D): CSF NfL, (E): plasma t-429 
tau, (F): CSF t-tau. Patients were subdivided into two groups according to the cut-off 430 
biomarker levels. The cut-off value in each graph was set as the median value of the 431 
corresponding biomarker within the ALS group. The squares and circles indicate an 432 
event (death, tracheostomy, or invasive ventilation). The red lines with red squares 433 
represent patients with levels of biomarkers no lower than the cut-off (the high-level 434 
group). The black lines with black circles represent those with levels lower than the cut-435 
off (the low-level group). 436 
 437 
Figure 5 438 
ROC analyses for the composite parameters of the discovery and validation cohorts. 439 
AUC values are indicated in the graphs. The title of each graph represents the biomarker 440 
used as an independent variable on analysis: (A): the products of CSF NfL and CSF 441 
TDP-43 in the discovery cohort; the red and blue dotted lines respectively indicate the 442 
ROC curves of CSF NfL alone and CSF TDP 43 alone for reference (see Supplementary 443 
Figure 1 and 3 regarding the ROC analyses of each biomarker for details).  (B): the 444 
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products of plasma NfL and CSF NfL in the discovery cohort; the red and blue dotted 445 
lines respectively indicate the ROC curves of CSF NfL alone and plasma NfL alone. 446 
(C): the products of plasma NfL and CSF TDP-43 in the discovery cohorts; the red and 447 
blue dotted lines respectively indicate the ROC curves of CSF TDP-43 alone and 448 
plasma NfL alone. (D): the products of CSF NfL and CSF TDP-43 in the validation 449 
cohort; the red and blue dotted lines respectively indicate the ROC curves of CSF NfL 450 
alone and TDP-43 alone. 451 
 452 
Figure 6 453 
Scatter plots of biomarkers levels in combined analysis of the discovery and validation 454 
cohorts. 455 
Analyses of plasma biomarkers involved 49 ALS patients and 47 controls; CSF 456 
biomarker analyses involved 71 ALS patients and 68 controls. Levels of plasma and 457 
CSF TDP-43 (A, B), NfL (B, C), t-tau (D, E) are presented. Because of inter-assay 458 
variation, we corrected the values of the validation cohort based on the correction 459 
formula: raw values x correction factors. The correction factors were determined as the 460 
mean value ratios between the discovery and validation assays based on four internal 461 
controls for each biomarker. Bars indicate median values. The P-value generated by 462 
Mann-Whitney’s U test between the ALS and whole control groups is presented above 463 
each graph. n.s: not significant. 464 
 465 
Figure 7 466 
Kaplan-Meier survival curves in ALS patients on combined analysis of the discovery 467 
and validation cohorts. 468 
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Correction of interassay variation was conducted using the formula presented in Figure 469 
5. (A): plasma TDP-43, (B): CSF TDP-43, (C): plasma NfL, (D): CSF NfL, (E): plasma 470 
t-tau, (F): CSF t-tau. Patients were subdivided into two groups according to the cut-off 471 
biomarker levels. The cut-off value in each graph was set as the median value of the 472 
corresponding biomarker within the ALS group. The squares and circles indicate an 473 
event (death, tracheostomy, or invasive ventilation). The red lines with red squares 474 
represent patients with levels of biomarkers no lower than the cut-off (the high-level 475 
group). The black lines with black circles represent those with levels lower than the cut-476 
off (the low-level group). 477 
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